As part of the August issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief editor Marc Humbert discusses the publication of the results of a trial of fevipiprant, an oral prostaglandin in DP2 receptor (CRTh2) antagonist, in allergic asthma that is not controlled by low-dose inhaled corticosteroids with Prof. Eric D. Bateman from the University of Cape Town, South Africa.